Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 29 Issue 1, January 2023

Liquid biopsies in colorectal cancer

In this issue, Oki et al. show an association between circulating tumor DNA after surgery and recurrence risk in patients with colorectal cancer. The test tube on the cover contains a mixture of red blood cells, immune cells and circulating tumor DNA, reflecting the ability of personalized sequencing technology to identify residual disease at the molecular level, which can in turn help optimize patient management.

See Article

Image: Natera, Inc. Cover design: Marina Spence

Editorial

Top of page ⤴

News

Top of page ⤴

News Feature

Top of page ⤴

Correspondence

Top of page ⤴

Comment

  • Technological innovation and changes to regulation are disrupting the hearing health sector, with implications for data privacy, product safety and accessibility, and provide challenges and opportunities for equitable hearing health.

    • Isabelle Boisvert
    • Adam G. Dunn
    • Melanie Calvert
    Comment
Top of page ⤴

World View

Top of page ⤴

News & Views

  • A phase 1 trial using an allogeneic stem-cell-based therapy in people with progressive multiple sclerosis (MS) shows the feasibility and tolerability of the approach; rigorous evaluation of this and other regenerative strategies for MS is now urgently needed.

    • Valentina Fossati
    • Luca Peruzzotti-Jametti
    • Stefano Pluchino
    News & Views
  • As another clinical trial of a mitochondria-targeting cancer therapy faces failure, it calls for a thorough re-evaluation of the strategy; the time has come to go from the bedside back to the bench.

    • Xue Zhang
    • Chi V. Dang
    News & Views
  • Automated insulin delivery systems that are already used in type 1 diabetes show promise for patients with type 2 diabetes, and are poised to have a substantial effect on public health.

    • Roy W. Beck
    News & Views
Top of page ⤴

Research Briefings

  • Clinical trials in neurological diseases often involve subjective, qualitative endpoints, such ‘by eye’ observations of movement. We developed an artificial intelligence–based method to analyze natural daily behavior data from people with Duchenne muscular dystrophy, using machine-learning algorithms to accurately predict their personal disease trajectories better than conventional clinical assessments.

    Research Briefing
  • The large, ongoing CIRCULATE-Japan trial is investigating the role of circulating tumor DNA (ctDNA)-based molecular residual disease testing in patients with resectable colorectal cancer after radical surgery. An interim analysis of GALAXY, a prospective, observational arm of CIRCULATE-Japan, establishes ctDNA as a prognostic and predictive biomarker.

    Research Briefing
  • The cause of pregnancy loss or perinatal death often remains unexplained, even following a standard autopsy. Comprehensive genomic investigation of pregnancy loss or perinatal death identifies a cause in over 50% of cases, particularly where congenital abnormalities are present. Causes of stillbirths without congenital abnormalities remain difficult to identify.

    Research Briefing
  • By performing a large-scale biobank-based genome-wide association study, we identified a strong link between the underlying risk of cardiometabolic disease and patterns of lifelong medication use in hyperlipidemia, hypertension and type 2 diabetes. We discover hundreds of genetic predictors of medication use behavior and show medication-use-enhanced applications for polygenic prediction in cardiometabolic diseases.

    Research Briefing
  • We demonstrate the power of a data-informed medicines-based approach in discovering the indirect effect of the COVID-19 pandemic on cardiovascular events using 1.32 billion records of dispensed medications in England, Scotland and Wales. We estimate that interruption of preventive care could result in more than 13,000 extra cardiovascular events.

    Research Briefing
  • A machine learning algorithm identifies four reproducible clinical subphenotypes of long COVID from the electronic health records of patients with post-acute sequelae of SARS-CoV-2 infection within 30–180 days of infection; these patterns have implications for the treatment and management of long COVID.

    Research Briefing
Top of page ⤴

Perspectives

  • Moving away from the traditional ‘tumor-centric’ view, the authors explore how systemic biology, as well as aging, co-morbidities and co-medications, all interact and influence cancer development and progression.

    • Guido Kroemer
    • Jennifer L. McQuade
    • Laurence Zitvogel
    Perspective
Top of page ⤴

Articles

Top of page ⤴

Search

Quick links